BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 33417137)

  • 1. Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid.
    Fujioka Y; Hata N; Akagi Y; Kuga D; Hatae R; Sangatsuda Y; Michiwaki Y; Amemiya T; Takigawa K; Funakoshi Y; Sako A; Iwaki T; Iihara K; Mizoguchi M
    J Neurooncol; 2021 Mar; 152(1):47-54. PubMed ID: 33417137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applications of cerebrospinal fluid circulating tumor DNA in the diagnosis of gliomas.
    Zhao Z; Zhang C; Li M; Shen Y; Feng S; Liu J; Li F; Hou L; Chen Z; Jiang J; Ma X; Chen L; Yu X
    Jpn J Clin Oncol; 2020 Mar; 50(3):325-332. PubMed ID: 32039443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid.
    Martínez-Ricarte F; Mayor R; Martínez-Sáez E; Rubio-Pérez C; Pineda E; Cordero E; Cicuéndez M; Poca MA; López-Bigas N; Ramon Y Cajal S; Vieito M; Carles J; Tabernero J; Vivancos A; Gallego S; Graus F; Sahuquillo J; Seoane J
    Clin Cancer Res; 2018 Jun; 24(12):2812-2819. PubMed ID: 29615461
    [No Abstract]   [Full Text] [Related]  

  • 4. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma.
    Huang TY; Piunti A; Lulla RR; Qi J; Horbinski CM; Tomita T; James CD; Shilatifard A; Saratsis AM
    Acta Neuropathol Commun; 2017 Apr; 5(1):28. PubMed ID: 28416018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquid biopsy for pediatric diffuse midline glioma: a review of circulating tumor DNA and cerebrospinal fluid tumor DNA.
    Azad TD; Jin MC; Bernhardt LJ; Bettegowda C
    Neurosurg Focus; 2020 Jan; 48(1):E9. PubMed ID: 31896079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standardization of the liquid biopsy for pediatric diffuse midline glioma using ddPCR.
    Li D; Bonner ER; Wierzbicki K; Panditharatna E; Huang T; Lulla R; Mueller S; Koschmann C; Nazarian J; Saratsis AM
    Sci Rep; 2021 Mar; 11(1):5098. PubMed ID: 33658570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Muralidharan K; Yekula A; Small JL; Rosh ZS; Kang KM; Wang L; Lau S; Zhang H; Lee H; Bettegowda C; Chicoine MR; Kalkanis SN; Shankar GM; Nahed BV; Curry WT; Jones PS; Cahill DP; Balaj L; Carter BS
    Clin Cancer Res; 2021 Jan; 27(1):169-178. PubMed ID: 33051308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDH1 p.R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-mutant gliomas.
    Fujita Y; Nunez-Rubiano L; Dono A; Bellman A; Shah M; Rodriguez JC; Putluri V; Kamal AHM; Putluri N; Riascos RF; Zhu JJ; Esquenazi Y; Ballester LY
    J Neurooncol; 2022 Sep; 159(2):261-270. PubMed ID: 35816267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomas.
    Diplas BH; Liu H; Yang R; Hansen LJ; Zachem AL; Zhao F; Bigner DD; McLendon RE; Jiao Y; He Y; Waitkus MS; Yan H
    Neuro Oncol; 2019 Mar; 21(4):440-450. PubMed ID: 30346624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The Present and Future of Less-invasive Liquid Biopsy for the Diagnosis of Gliomas and Brain Tumors].
    Natsumeda M; On J; Watanabe J; Tsukamoto Y; Okada M; Fujii Y; Adachi J; Nishikawa R
    No Shinkei Geka; 2021 May; 49(3):527-534. PubMed ID: 34092558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TERT Promoter Mutation Analysis to Distinguish Glioma From Gliosis.
    Hewer E; Phour J; Gutt-Will M; Schucht P; Dettmer MS; Vassella E
    J Neuropathol Exp Neurol; 2020 Apr; 79(4):430-436. PubMed ID: 32068851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic implications of TERT promoter mutation status in diffuse gliomas in a routine clinical setting.
    Hewer E; Prebil N; Berezowska S; Gutt-Will M; Schucht P; Dettmer MS; Vassella E
    Virchows Arch; 2017 Nov; 471(5):641-649. PubMed ID: 28823044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electronic DNA Analysis of CSF Cell-free Tumor DNA to Quantify Multi-gene Molecular Response in Pediatric High-grade Glioma.
    Bruzek AK; Ravi K; Muruganand A; Wadden J; Babila CM; Cantor E; Tunkle L; Wierzbicki K; Stallard S; Dickson RP; Wolfe I; Mody R; Schwartz J; Franson A; Robertson PL; Muraszko KM; Maher CO; Garton HJL; Qin T; Koschmann C
    Clin Cancer Res; 2020 Dec; 26(23):6266-6276. PubMed ID: 33087334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy.
    Panditharatna E; Kilburn LB; Aboian MS; Kambhampati M; Gordish-Dressman H; Magge SN; Gupta N; Myseros JS; Hwang EI; Kline C; Crawford JR; Warren KE; Cha S; Liang WS; Berens ME; Packer RJ; Resnick AC; Prados M; Mueller S; Nazarian J
    Clin Cancer Res; 2018 Dec; 24(23):5850-5859. PubMed ID: 30322880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IDH1 mutation detection by droplet digital PCR in glioma.
    Wang J; Zhao YY; Li JF; Guo CC; Chen FR; Su HK; Zhao HF; Long YK; Shao JY; To Ss; Chen ZP
    Oncotarget; 2015 Nov; 6(37):39651-60. PubMed ID: 26485760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular profiling of tumors of the brainstem by sequencing of CSF-derived circulating tumor DNA.
    Pan C; Diplas BH; Chen X; Wu Y; Xiao X; Jiang L; Geng Y; Xu C; Sun Y; Zhang P; Wu W; Wang Y; Wu Z; Zhang J; Jiao Y; Yan H; Zhang L
    Acta Neuropathol; 2019 Feb; 137(2):297-306. PubMed ID: 30460397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
    Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
    Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation.
    Orzan F; De Bacco F; Lazzarini E; Crisafulli G; Gasparini A; Dipasquale A; Barault L; Macagno M; Persico P; Pessina F; Bono B; Giordano L; Zeppa P; Melcarne A; Cassoni P; Garbossa D; Santoro A; Comoglio PM; Indraccolo S; Simonelli M; Boccaccio C
    Clin Cancer Res; 2023 Apr; 29(7):1252-1266. PubMed ID: 36648487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.